Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $67.00 Average Price Target from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $67.00.

NTLA has been the topic of several research reports. Wedbush restated a "neutral" rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Thursday, February 15th. Wolfe Research assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. Canaccord Genuity Group upped their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Friday, February 23rd. Finally, The Goldman Sachs Group cut shares of Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the company from $136.00 to $32.00 in a research note on Friday, February 23rd.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded down $0.19 on Friday, hitting $24.78. The company's stock had a trading volume of 879,567 shares, compared to its average volume of 1,553,310. Intellia Therapeutics has a fifty-two week low of $22.67 and a fifty-two week high of $47.48. The firm's fifty day moving average price is $27.68 and its 200-day moving average price is $28.48. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -4.58 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The firm had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same quarter last year, the firm posted ($1.40) EPS. Analysts predict that Intellia Therapeutics will post -5.58 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of the company's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Intellia Therapeutics news, EVP Laura Sepp-Lorenzino sold 2,275 shares of the business's stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $28.87, for a total transaction of $65,679.25. Following the sale, the executive vice president now directly owns 43,927 shares of the company's stock, valued at approximately $1,268,172.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP James Basta sold 2,297 shares of the company's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares in the company, valued at $2,691,027.29. The disclosure for this sale can be found here. 3.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently modified their holdings of NTLA. Los Angeles Capital Management LLC boosted its stake in Intellia Therapeutics by 49.2% during the first quarter. Los Angeles Capital Management LLC now owns 17,449 shares of the company's stock worth $480,000 after acquiring an additional 5,754 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Intellia Therapeutics by 209.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,561 shares of the company's stock worth $322,000 after acquiring an additional 7,151 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Intellia Therapeutics during the fourth quarter worth $9,086,000. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company's stock worth $254,514,000 after acquiring an additional 155,579 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Intellia Therapeutics by 3.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 824,527 shares of the company's stock worth $25,140,000 after acquiring an additional 28,264 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.